Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586892 · ClinicalTrials.gov registry record
Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)
A clinical trial of Orodental Injury, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06586892: Recruiting study of Orodental Injury, sponsored by M.D. Anderson Cancer Center.
NCT06586892 is a study of Orodental Injury that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06586892, a study of Orodental Injury, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This research will focus on the prospective qualification and validation of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) candidate biomarkers (i.e., Ktrans and Ve) to assess the natural history of osteoradionecrosis (ORN) and treatment for this devastating complication related to irradiation of head and neck cancers. The investigations will also include assessment of DCE-MRI candidate biomarkers for pre-qualification as quantitative imaging biomarkers of soft-tissue structures.
Conditions Studied
Interventions
- BEHAVIORAL Radiotherapy followed by chemotherapy
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2032-12-30 |
What NCT06586892 shows while recruiting
NCT06586892 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Orodental Injury appearing as the primary indexed condition, and to 1 intervention - of which Radiotherapy followed by chemotherapy is the first listed.
NCT06586892 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06586892 about?
NCT06586892 is a clinical study titled "Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)". This research will focus on the prospective qualification and validation of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) candidate biomarkers (i.e., Ktrans and Ve) to assess the natural history of osteoradionecrosis (ORN) and treatment for this devastating complication related to i...
What is the current status of trial NCT06586892?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-09-15. Estimated completion is 2032-12-30.
What conditions does trial NCT06586892 study?
This clinical trial studies the following conditions: Orodental Injury.
What interventions are being tested in trial NCT06586892?
The interventions under investigation include: Radiotherapy followed by chemotherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06586892?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586892 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI